NVS vs. RGEN: Novartis vs. Repligen Stock Comparison

November 11, 2026

How do Novartis (NVS) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Novartis (NVS) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVS is classified in Pharmaceuticals while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) trades as ordinary local shares, while Novartis (NVS) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Novartis (NVS) and Repligen (RGEN)
Profile Item	NVS	RGEN
Name	Novartis AG Sponsored ADR	Repligen Corporation
Country/Region	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	307.00 billion USD	11.09 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 7, 1996	April 29, 1986
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

NVS

RGEN

GSPC

Novartis (NVS) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Novartis (NVS) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Novartis (NVS) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Total Return (1Y)	32.98%	23.28%
Total Return (3Y, Annualized)	24.72%	6.20%
Total Return (5Y, Annualized)	18.80%	-8.41%

Risk Profile

Drawdown History

NVS

RGEN

GSPC

Novartis (NVS) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Novartis (NVS) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Volatility (1Y, Annualized)	27.12%	46.73%
Beta (5Y)	0.41	1.11
Max Drawdown (5Y)	-20.42%	-64.67%
Avg. Volume (3M)	2.07M	1.18M

Risk-Adjusted Performance

Risk-Return Positioning

NVS and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Sharpe Ratio (1Y)	1.06	0.41
Sortino Ratio (1Y)	1.46	0.60

Profitability

ROE (TTM)

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Novartis (NVS) reports 24.33%, ranking against industry peers normally.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.33%

Max: 109.18%
NVS: 24.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max: 109.18%
Q3: 6.23%
RGEN: -0.57%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Novartis (NVS) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Novartis (NVS) reports 17.49%, ranking against industry peers normally.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.49%

Max: 18.05%
NVS: 17.49%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
RGEN: -1.47%
Q1: -4.14%
Min: -17.05%

Novartis (NVS) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Novartis (NVS) at 34.27% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.27%

Max: 83.12%
NVS: 34.27%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max: 83.12%
Q3: 14.77%
RGEN: 6.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Novartis (NVS) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
ROE (TTM)	24.33%	-0.57%
ROA (TTM)	10.86%	1.40%
Net Margin (TTM)	17.49%	-1.47%
Operating Margin (TTM)	34.27%	6.19%
Gross Margin (TTM)	75.21%	53.77%

Growth

Revenue Growth

Both Novartis (NVS) at 9.57% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Novartis (NVS) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Novartis (NVS) reports EPS growth of 21.81%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Novartis (NVS) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Revenue Growth (YoY)	9.57%	16.36%
Revenue Growth (3Y CAGR)	9.25%	-2.70%
EPS Growth (YoY)	21.81%	--
EPS Growth (3Y CAGR)	31.14%	-35.73%

Financial Strength

Current Ratio (MRQ)

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Novartis (NVS) at 0.88 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVS.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
NVS: 0.88
Min: 0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max: 25.13
Q3: 12.13
RGEN: 9.88
Median: 5.52
Q1: 2.47
Min: 0.10

Novartis (NVS) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Repligen (RGEN) at 0.33 carries an industry-typical debt-to-equity mix, while Novartis (NVS) at 1.29 uses more debt funding than most peers.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max: 1.42
NVS: 1.29
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max: 1.42
Q3: 0.65
RGEN: 0.33
Median: 0.15
Q1: 0.02
Min: 0.00

Novartis (NVS) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Current Ratio (MRQ)	0.88	9.88
Debt / Equity (MRQ)	1.29	0.33
Net Debt / EBITDA	1.64	-1.19

Dividends

Dividend Yield (TTM)

Repligen (RGEN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a yield of 2.88%, ranking against industry peers normally.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.88%

NVS: 2.88%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Novartis (NVS) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Repligen (RGEN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novartis (NVS) reports a payout of 90.46%, ranking against industry peers normally.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

90.46%

NVS: 90.46%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Novartis (NVS) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
Dividend Yield (TTM)	2.88%	0.00%
Dividend Payout Ratio (TTM)	90.46%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Novartis (NVS) trades at 31.02 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.02

Max: 85.34
Q3: 43.46
NVS: 31.02
Median: 26.69
Q1: 13.30
Min: 0.07

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RGEN: --

Novartis (NVS) vs. Repligen (RGEN): RGEN does not report P/E ratio, so it has no value marker; NVS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Novartis (NVS) at 5.35 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.35

Max: 58.18
Q3: 25.77
Median: 7.30
NVS: 5.35
Q1: 3.01
Min: 0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max: 58.18
Q3: 25.77
RGEN: 13.77
Median: 7.30
Q1: 3.01
Min: 0.01

Novartis (NVS) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while Novartis (NVS) at 8.25 carries an above-peer premium to book — NVS is pricier on assets.

NVS

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.25

Max: 13.53
NVS: 8.25
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
RGEN: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

Novartis (NVS) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Novartis (NVS) and Repligen (RGEN)
Metric	NVS	RGEN
P/E Ratio (TTM)	31.02	--
P/S Ratio (TTM)	5.35	13.77
P/B Ratio (MRQ)	8.25	4.70
Free Cash Flow Yield (TTM)	3.67%	1.01%